AK 0707
Alternative Names: AK-0707Latest Information Update: 13 Apr 2023
At a glance
- Originator Ark Biosciences
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
- Preclinical Scleroderma
Most Recent Events
- 13 Apr 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis in China (unspecified route) prior to April 2023 (Ark Biosciences pipeline, April 2023)
- 14 Sep 2022 Preclinical trials in Scleroderma in China (unspecified route) (Ark Bioscience pipeline, September 2022)
- 03 Jan 2022 Preclinical trials in Idiopathic pulmonary fibrosis in China (unspecified route) (Ark Biosciences pipeline, January 2022)